Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 692 participants.

Also called NCT07263776

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 692 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07263776
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07263776. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-09-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
Acronym
IRIS-2
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tocilizumab
Intervention (Drug)
Placebo
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct07263776
Content hash
137d1b48d921486403aa2587926b1f726119fa7632c0033d823814339c086406